Bui Thuy, Grygiel Richard, Konstantatos Alex, Christelis Nick, Liew Susan, Hopkins Ria, Dooley Michael
Pharmacy Department, Alfred Health, Melbourne, Australia; Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia.
Pharmacy Department, Alfred Health, Melbourne, Australia.
J Opioid Manag. 2020 May/Jun;16(3):167-176. doi: 10.5055/jom.2020.0565.
Many patients are discharged from hospital after surgery with excessive doses of opioid, and prescription opioid addiction has become a serious public health problem. Inpatient opioid de-escalation performed by clinical phar-macists may assist in reducing opioids before discharge. We aimed to evaluate whether clinical pharmacist-led opioid de-escalation for inpatients after orthopedic surgery led to significant reductions in opioid use at discharge, without resulting in greater pain intensity and side effects.
This retrospective pre-/post-intervention study evaluated patients before and after implementation of a phar-macist-led opioid de-escalation service.
A major tertiary institution.
Ninety eight participants underwent de-escalation, and 98 controls received standard care following ortho-pedic surgery.
Pharmacist-led opioid de-escalation was initiated after discharge from the institution's Acute Pain Service.
Primary outcome was total morphine oral equivalence (MOE) required in the 24-hours before discharge between the two groups. Secondary outcomes included pain intensity scores and opioid-related side effects.
The post-intervention group used significantly less opioids in the 24 hours preceding discharge compared with the precohort (total MOE 30 vs 45 mg; p = 0.025).There were no differences in pain intensity at rest (p = 0.19) or with movement (p = 0.19). Cases experienced significantly less constipation (29 vs 49 percent; p = 0.004); no differences were observed for other side effects.
We observed statistically similar pain intensity ratings, in the setting of significantly lowered opioid doses among the post-intervention group prior to discharge.
Pharmacist-led inpatient opioid de-escalation is effective, does not increase pain intensity, and reduces constipation. Hospitals should explore the viability of extending pharmacist-led opioid de-escalation to other surgical patients and following hospital discharge, aiming for opioid cessation.
许多患者术后出院时携带过量阿片类药物,处方阿片类药物成瘾已成为严重的公共卫生问题。临床药师进行的住院患者阿片类药物减量可能有助于在出院前减少阿片类药物的使用。我们旨在评估临床药师主导的骨科手术后住院患者阿片类药物减量是否能显著减少出院时的阿片类药物使用量,同时又不会导致疼痛强度增加和副作用增多。
这项回顾性干预前后研究评估了实施药师主导的阿片类药物减量服务前后的患者情况。
一家大型三级医疗机构。
98名参与者接受了减量治疗,98名对照者在骨科手术后接受了标准护理。
从该机构的急性疼痛服务部门出院后开始由药师主导的阿片类药物减量。
主要结局是两组患者出院前24小时所需的总吗啡口服当量(MOE)。次要结局包括疼痛强度评分和阿片类药物相关副作用。
与干预前队列相比,干预后组在出院前24小时使用的阿片类药物明显更少(总MOE为30 mg对45 mg;p = 0.025)。静息时(p = 0.19)或活动时(p = 0.19)的疼痛强度没有差异。病例便秘发生率显著降低(29%对49%;p = 0.004);其他副作用未观察到差异。
我们观察到,在干预后组出院前阿片类药物剂量显著降低的情况下,疼痛强度评分在统计学上相似。
药师主导的住院患者阿片类药物减量是有效的,不会增加疼痛强度,并能减少便秘。医院应探索将药师主导的阿片类药物减量扩展到其他手术患者并在出院后持续进行以实现阿片类药物停用的可行性。